Skip to content

Find our latest news, stories and press releases

Delivering long-term value for our stakeholders

Explore career opportunities and more

Impacting health for humanity

  1. Home/
  2. Our company/
  3. In Front of Cancer: Mary’s Story
Mary Guckert, Vice President, Oncology Delivery Unit, Global Development, Johnson & Johnson sitting at a table being interviewed

In Front of Cancer: Mary’s Story

Each day, we are working toward our ambition to get in front of cancer.

For Mary Guckert, Vice President, Oncology Delivery Unit, Global Development, Johnson & Johnson, this work is deeply personal. Her story, and the stories of patients everywhere, inspire and remind us why we will never settle until the disease is behind everyone.

More from Johnson & Johnson

The future of immunology

Learn about the advances Johnson & Johnson is making to potentially help treat the millions of people living with conditions in which the immune system mistakenly damages healthy cells in the body.

What is inflammation?

Inflammation is the body’s natural response to injury or infection. But when it lingers, inflammation can lead to immune-mediated inflammatory diseases. Learn how Johnson & Johnson is innovating to help bring relief to those living with chronic inflammatory conditions.

What is IL-23?

This pro-inflammatory protein is the target of potential Johnson & Johnson medications that could help treat immune-mediated diseases such as psoriasis, inflammatory bowel disease and rheumatoid arthritis.